Prekallikrein (PK) deficiency is extremely rare, and manifestations are not well characterized due to a small number of cases reported and the lack of scientific clarity about its role in clot formation in vivo. Here, we report a case of a 64-year-old male, with no known history of abnormal bleeding, who scheduled to undergo deep brain stimulator placement for control of his Parkinson’s disease. During pre-procedure testing, activated partial thromboplastin time (PTT) was found to be prolonged at 146 seconds. Mixing studies were suggestive of a coagulation factor deficiency. His PTT characteristically became shorter with prolonged incubation, providing a clue at testing for PK levels, which were found to be severely low. He, subsequently, underwent surgery without any complications. Our case further highlights the clinical pearls for diagnosis and further endorses that these patients can safely undergo surgical procedures without the need for plasma transfusions or factor concentrate usage.
Prekallikrein (PK) is a glycoprotein involved in the intrinsic pathway of the coagulation system. PK deficiency is extremely rare, with only a small number of cases reported. Thus, manifestations of PK deficiency are not well characterized. Here, we report a case of a patient with PK deficiency scheduled to undergo a neurosurgical procedure.
A 64-year-old African American male was admitted to the hospital with a syncopal episode. His past medical history was significant for Parkinson’s disease, mild cognitive impairment, hypertension, and diabetes mellitus type 2. Past surgical history was notable for bilateral rotator cuff repair and appendectomy. There was no reported personal or family history of easy bruising, nose bleeds, bleeding gums, abnormal bleeding after surgery, thrombosis, or abnormal coagulation tests. His home medications did not include any antiplatelet or anticoagulation medications. He reported occasional alcohol use, but denied smoking or illicit drug use.
His admission vital signs were normal, and his physical exam was unremarkable with the exception of generalized rigidity and impaired balance. The only remarkable finding on the initial labs was an elevated partial thromboplastin time (PTT) of 40 seconds (25-35 seconds).
He was diagnosed with syncope secondary to dysautonomia and he was scheduled for deep brain stimulator placement. Since the PTT was mildly elevated, coagulation labs were repeated. He was also started on subcutaneous Lovenox for deep venous thrombosis prophylaxis.
Repeat coagulation labs revealed a normal prothrombin time/international normalized ratio (PT/INR) of 12.9 seconds/0.9 (11-14 seconds/<1.1) but a prolonged PTT of 55 seconds. The test was performed the same day, and the results showed a PT/INR of >100 seconds/>12 and a PTT >200 seconds. Coagulation times when repeated on the same sample revealed a PT/INR of 12.1 seconds/0.9 and an elevated PTT of 146 seconds. This prompted a new sample to be sent out again. The coagulation test results at this time showed a PTT of 46 seconds. Given the unexplained variation in results on the samples, heparin contamination and sample mix ups were ruled out. The lab technicians also recalibrated the machines and control, but continued to get different results for PTT even when sent to different coagulation labs within our health system.
The hematology/oncology service was consulted, and mixing studies were performed. The elevated PTTs corrected from 146 to 30 seconds and from 69 to 30 seconds after a 1:1 mix with normal plasma, indicating a factor deficiency as the likely cause of the prolonged PTT. Von Willebrand factor antigen, ristocetin cofactor activity, factor VIII, factor IX, factor XI, and factor XII levels were all found to be within normal limits. In the absence of a deficiency in the intrinsic pathway coagulation factors, and because of the unexplained sample to sample variation in the PTT, PK deficiency was suspected. Therefore, a PK level was obtained from a reference lab which revealed an activity of less than 1%, solidifying the diagnosis of PK deficiency. The patient was cleared for surgery by hematology/oncology and he underwent the procedure without any bleeding complications.
PK is a glycoprotein synthesized in the liver with its gene located on chromosome 4 . It circulates in the plasma bound to high molecular weight kallikrein (HMWK) with only 20% in free form. The inactive PK is converted to the active kallikrein by factor XIIa and also by the proteins derived from the endothelial cells . Kallikrein, in turn, regulates activation of factor XII to XIIa and the formation of bradykinin from HMWK before it is rapidly degraded in plasma by alpha-2 microglobulin and C1 esterase. Although not well characterized, PK is also believed to be implicated in the activation of plasminogen, decreasing blood pressure and increasing capillary permeability. There is data on both decreased and normal fibrinolytic activity with PK deficiency, but no clinically significant effects have been reported so far on blood pressure or capillary permeability .
PK deficiency was first reported in the Fletcher family in Kentucky in 1965 by Hathaway et al. . In 1973, Wuepper et al. showed that the “Fletcher factor” was actually PK . It is an autosomal recessive disorder with more than seven different types of mutation identified by molecular genetic analysis . PK deficiency has been classified as type I and type II based on the level of activity and antigen. Type I, seen in 80% of cases, exhibits deficiency in both activity and antigen, whereas type II is associated with deficient activity and normal antigen levels.
The exact prevalence of PK deficiency is unknown. So far less than 100 cases have been reported in the literature and it is likely that it is underreported as it is not associated with bleeding, thrombosis or any other severe clinical symptoms . In the majority of cases that have been reported, patients underwent numerous procedures without any bleeding complications . Although case reports exist where patients with bleeding were found to have PK deficiency, almost all of them are more than 20 years old when coagulation testing may have been incomplete. Some other case reports have also attributed PK deficiency to cases with arterial and venous thrombosis, but recent studies have suggested that most of these patients had other risk factors for thrombosis . Recent clinical experience and studies make it evident that PK deficiency manifests the same way as factor XII deficiency, does not lead to bleeding, and does not prevent thrombosis.
PK deficiency largely presents as a marked elevation in PTT with a normal PT/INR and thrombin time (TT). Bleeding, however, is not seen as factors downstream (factor XII, factor XI, etc.) can be auto-activated or activated by other factors like thrombin or factor II. The PTT, therefore, decreases and can normalize if incubated long enough, thus explaining the sample to sample variability that is often noticed with PK deficiency, as highlighted in our patient . Additionally, variation in PTT prolongation may be seen depending on the type of reagent used, which include silica, ellagic acid, and kaolin . PK’s activity is tested similarly to other factors. Its antigen level can be tested by enzyme-linked immunosorbent assay (ELISA).
The prognosis of a patient with PK deficiency is the same as the normal patient population; therefore, do not require specific therapy. Its clinical significance is in patients on heparin treatment being monitored with the PTT since PK deficiency falsely elevates the PTT. Thus, anti-Xa level monitoring is recommended. Those with thrombosis are treated according to the guidelines for normal patients with similar thrombosis or thrombosis risk.
This case highlights the diagnostic challenge of PK deficiency and the diagnostic pearls that can help clinicians quickly hone in on the correct diagnosis. Our case further corroborates the belief that despite extreme prolongation of the PTT, patients with PK deficiency do not exhibit signs or symptoms of abnormal bleeding, and are not at increased risk for bleeding compared to the general population when undergoing a surgical intervention. Therefore, neither transfusion of plasma nor infusion of factor concentrates is necessary for these patients. Lastly, the monitoring of heparin therapy, using the anti-Xa instead of the PTT, is an important clinical consequence of PK deficiency.
- Bojanini EU, Loaiza-Bonilla A, Pimentel A: Prekallikrein deficiency presenting as recurrent cerebrovascular accident: case report and review of the literature. Case Rep Hematol. 2012, 2012:723204. 10.1155/2012/723204
- Girolami A, Scarparo P, Candeo N, Lombardi AM: Congenital prekallikrein deficiency. Expert Rev Hematol. 2010, 3:685-695. 10.1586/ehm.10.69
- Hathaway WE, Belhasen LP, Hathaway HS: Evidence for a new plasma thromboplastin factor I. Case report, coagulation studies and physicochemical properties. Blood. 1965, 26:521-532.
- Wuepper KD: Prekallikrein deficiency in man. J Exp Med. 1973, 138:1345-1355. 10.1084/jem.138.6.1345
- Nakao T, Yamane T, Katagami T, et al.: Severe prekallikrein deficiency due to a homozygous Trp499Stop nonsense mutation. Blood Coagul Fibrinolysis. 2011, 22:337-339. 10.1097/MBC.0b013e3283444ddb
- Dasanu CA, Alexandrescu DT: A case of prekallikrein deficiency resulting in severe recurrent mucosal hemorrhage. Am J Med Sci. 2009, 338:429-430. 10.1097/MAJ.0b013e3181b270bb
- Unal S, Jariwala PD, Mahoney DH, Teruya J: A challenging diagnosis of homozygous prekallikrein deficiency during the preoperative evaluation of an infant with intractable seizures: a literature review of surgical management in this disorder. Lab Med. 2010, 41:271-274. 10.1309/LM5VS8FIFRF1OHCT
- Girolami A, Allemand E, Bertozzi I, Candeo N, Marun S, Girolami B: Thrombotic events in patients with congenital prekallikrein deficiency: a critical evaluation of all reported cases. Acta Haematol. 2010, 123:210-214. 10.1159/000313361
- Asmis LM, Sulzer I, Furlan M, Lammle B: Prekallikrein deficiency: the characteristic normalization of the severely prolonged aPTT following increased preincubation time is due to autoactivation of factor XII. Thrombosis Res. 2002, 105:463-470.
- Entes K, LaDuca FM, Tourbaf KD: Fletcher factor deficiency, source of variations of the activated partial thromboplastin time test. Am J Clin Pathol. 1981, 75:626-628. 10.1093/ajcp/75.4.626
Diagnostic Pearls and Clinical Implications of Prekallikrein Deficiency
Ethics Statement and Conflict of Interest Disclosures
Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Cite this article as:
Yasin H, Jamil M, Williams, Iii L A (May 29, 2020) Diagnostic Pearls and Clinical Implications of Prekallikrein Deficiency. Cureus 12(5): e8349. doi:10.7759/cureus.8349
Received by Cureus: January 15, 2018
Peer review began: August 01, 2018
Peer review concluded: May 20, 2020
Published: May 29, 2020
© Copyright 2020
Yasin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.